Home
Biosimilars & Biobetters USA
November 16 - November 17, 2015
Biosimilars & Biobetters USA

Building on last year's success, SAE Media Group's 2nd Annual Biosimilars & Biobetters USA returns to New Jersey in November! 

Biologic Therapeutics have revolutionised the treatment of many diseases and biosimilars are having a similar therapeutic efficacy with potentially lower costs to the health care system.


The approval of the first biosimilar in the US is expected to save the healthcare industry and patients $5.7 billion over the next decade. However, it is a complex landscape with complexity of manufacturing biologics making the development of biosimilars more challenging than the development of generics.


In addition to this, the upcoming patent cliffs facing manufacturers of blockbuster biologics are daunting – with over $60bn in branded biologic sales coming off patent in the next several years.


The biosimilars and biobetters industry is likely to become a lot more dynamic and strategic than we’ve seen with small molecule generics; there will begin to become a premium on flexibility and willingness to take chances in an ever-shifting competitive and regulatory environment.
 

The US biosimilars market is expected to reach $2 billion by 2018 and with the first biosimilar approved recently in America, this is an exciting time for the biosimilar field with approval in the US expected to increase during the next ten years. The regulatory landscape is evolving rapidly so it is important to understand the developments in the biosimilar guideline framework and the cohesion in legislation between the US and Europe.

The learning objectives in the US should be to fully understand the product lifecycle and all aspects of biosimilar research and development.

 

Watch this space…

 

Source - http://www.financierworldwide.com/competitive-strategies-in-life-sciences-biobetters-versus-biosimilars/#.VYBBtmVwbcs

FEATURED SPEAKERS

Andrea Laslop

Andrea Laslop

Head of Scientific Office, Austrian Agency for Health and Food Safety
Carsten Brockmeyer

Carsten Brockmeyer

CEO, Formycon AG
Cliff Mintz

Cliff Mintz

Senior Writer/Correspondent, Life Science Leader
Dominic Adair

Dominic Adair

Partner, Patent Litigation, Bristows
Gerry McGettigan

Gerry McGettigan

CEO & Regultory Expert; COO, Kinesys Consulting Ltd (UK); amp biosimilars AG (Germany)
Jim Nelson

Jim Nelson

Senior Principal and Owner, Adversarial Proceedings/Pharma & Biotech, Schwegman Lundberg Woessner
Magdalena Leszczyniecka

Magdalena Leszczyniecka

Founder and CEO, STC Biologics Inc
Michael Kleinrock

Michael Kleinrock

Research, Director, IMS Health Inc
Michael Tovey

Michael Tovey

INSERM Director of Research, Laboratory of Biotechnology and Applied Pharmacology, Ecole Normale Supérieure de Cachan
Raju Shantha

Raju Shantha

Scientific Director, Biologics Research, Janssen Pharmaceuticals, Inc.
Richard Dicicco

Richard Dicicco

Chairman, Harvest Moon Pharmaceuticals
Robin Chadwick

Robin Chadwick

Principal, Biotechnology, Schwegman Lundberg Woessner
Steinar Madsen

Steinar Madsen

Medical Director, Norwegian Medicines Agency
Takashi Kei  Kishimoto

Takashi Kei Kishimoto

Chief Scientific Officer, Selecta Biosciences

Andrea Laslop

Head of Scientific Office, Austrian Agency for Health and Food Safety
Andrea Laslop

Carsten Brockmeyer

CEO, Formycon AG
Carsten Brockmeyer

Catherine Godrecka-Bareau

Director of Portfolio Management & Strategy, Biosimilars, Merck Group
Catherine Godrecka-Bareau

Cliff Mintz

Senior Writer/Correspondent, Life Science Leader
Cliff Mintz

Dominic Adair

Partner, Patent Litigation, Bristows
Dominic Adair

Gerry McGettigan

CEO & Regultory Expert; COO, Kinesys Consulting Ltd (UK); amp biosimilars AG (Germany)
Gerry McGettigan

Graeme Deuchar

Product Development Expert, Kinesys Consulting Ltd
Graeme Deuchar

Jim Nelson

Senior Principal and Owner, Adversarial Proceedings/Pharma & Biotech, Schwegman Lundberg Woessner
Jim Nelson

Jordanis Joy

Biopharmaceutical Regulatory Affairs, Sandoz Inc
Jordanis Joy

Liz Yamashita

VP, Regulatory & Clinical Affairs, Oncobiologics
Liz Yamashita

Magdalena Leszczyniecka

Founder and CEO, STC Biologics Inc
Magdalena Leszczyniecka

Michael Kleinrock

Research, Director, IMS Health Inc
Michael Kleinrock

Michael Tovey

INSERM Director of Research, Laboratory of Biotechnology and Applied Pharmacology, Ecole Normale Supérieure de Cachan
Michael Tovey

Raju Shantha

Scientific Director, Biologics Research, Janssen Pharmaceuticals, Inc.
Raju Shantha

Rakesh Dixit

Vice President, R&D, Global Head, Biologics Safety Assessment, MedImmune Inc
Rakesh Dixit

Richard Dicicco

Chairman, Harvest Moon Pharmaceuticals
Richard Dicicco

Robin Chadwick

Principal, Biotechnology, Schwegman Lundberg Woessner
Robin Chadwick

Sam Mukherjee

Associate Director Biosimilar Commercial Strategy and Portfolio Management, Dr. Reddy's Laboratories Inc.
Sam Mukherjee

Steinar Madsen

Medical Director, Norwegian Medicines Agency
Steinar Madsen

Takashi Kei Kishimoto

Chief Scientific Officer, Selecta Biosciences
Takashi Kei  Kishimoto

Ted Carver

Principal Consultant, PAREXEL
Ted Carver

sponsors

Conference agenda

clock

8:30

Registration & Coffee

Ted Carver

Ted Carver, Principal Consultant, PAREXEL

Lotte McNamara

Lotte McNamara, Principal Consultant, PAREXEL

clock

9:00

Workshop Leader's Opening Remarks

clock

9:10

Evaluating How to Avoid Regulatory Pitfalls in Analytical Similarity Assessments

  • Quality systems/GMPs for biosimilar programs
  • Handling R&D analytical data for inspections
  • Documenting method qualification studies for similarity tests
  • clock

    10:45

    Morning Coffee

    clock

    11:15

    Assessing the Regulatory Quality Compliance Required for Biosimilars Approval

  • Distinctions between product comparability studies and similarity studies
  • Designing and conducting similarity studies- choosing adequate test attributes, comparators, and number of batches for similarity assessment
  • Addressing residual uncertainties in the analytical similarity programs
  • clock

    12:00

    Discussion & Q&A

    clock

    12:30

    Close of Workshop

    clock

    13:30

    Registration & Coffee

    clock

    14:00

    Introductions and Opening Remarks

    Gerry McGettigan

    Gerry McGettigan, CEO & Regulatory Expert; COO, Kinesys Consulting Ltd. (UK); amp biosimilars AG (Germany)

    Graeme Deuchar

    Graeme Deuchar, Product Development Expert, Kinesys Consulting Ltd

    Liz Yamashita

    Liz Yamashita, VP, Regulatory & Clinical Affairs, Oncobiologics

    clock

    14:15

    Session 1: Regulatory fundamentals and expedients

    Gerry McGettigan

    Gerry McGettigan, CEO & Regulatory Expert; COO, Kinesys Consulting Ltd. (UK); amp biosimilars AG (Germany)

    Graeme Deuchar

    Graeme Deuchar, Product Development Expert, Kinesys Consulting Ltd

    clock

    15:00

    Session 2: Commercial imperatives

    Gerry McGettigan

    Gerry McGettigan, CEO & Regulatory Expert; COO, Kinesys Consulting Ltd. (UK); amp biosimilars AG (Germany)

    Graeme Deuchar

    Graeme Deuchar, Product Development Expert, Kinesys Consulting Ltd

    clock

    15:30

    Coffee break

    clock

    16:00

    Session 3: Development requirements and options

    Gerry McGettigan

    Gerry McGettigan, CEO & Regulatory Expert; COO, Kinesys Consulting Ltd. (UK); amp biosimilars AG (Germany)

    Graeme Deuchar

    Graeme Deuchar, Product Development Expert, Kinesys Consulting Ltd

    clock

    17:00

    Discussion & Q&A

    clock

    17:30

    Close of Workshop

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Richard Dicicco

    Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals

    clock

    9:10

    FDA's views on statistical analysis of quality attributes to establish biosimilarity

    Ted Carver

    Ted Carver, Principal Consultant, PAREXEL

    clock

    9:50

    What can the US learn from European experiences?

    Steinar Madsen

    Steinar Madsen, Medical Director, Norwegian Medicines Agency

  • Nine years of biosimilars in Europe – safety and efficacy
  • What are the regulatory differences between Europe and the US?
  • How important  is labelling and naming?
  • Uptake of biosimilars in clinical practice – lessons from Europe
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    SPOTLIGHT PRESENTATION: The first biosimilar approved by the FDA

    Jordanis Joy

    Jordanis Joy, Biopharmaceutical Regulatory Affairs, Sandoz Inc

  • Looking at this case in detail, how did it progress and how will it develop
  • How did the FDA interpret their own guidelines
  • What can we learn from this first approval?
  • Looking ahead, what’s the future regarding more complex molecules?
  • clock

    11:40

    Panel Debate: Assessing the success criteria for commercialization for global biosimilars

  • Gain insights as to what an optimal business model is for global commercialization of biosimilars: 1)  stand alone; 2) generic partnered with Big Pharma or Big Bio; 3)geographical or regional licensees; 4) distributors; 5) consortia; 6) contract development/ manufacturing for fingerprint-like similarity
  • Which model for which products?   1) first wave biosimilars 2) second wave biosimilars 3)  Third wave biosimilars and PD-1s
  • Geographical location – which model for which region?  1) Europe; 2) USA; 3) LATAM; 4) APAC; 5) Russia and CIS 

     

  • Magdalena Leszczyniecka

    Magdalena Leszczyniecka, Founder and CEO, STC Biologics Inc

    Robin Chadwick

    Robin Chadwick, Principal, Biotechnology, Schwegman Lundberg Woessner

    Rakesh Dixit

    Rakesh Dixit, Vice President, R&D, Global Head, Biologics Safety Assessment, MedImmune Inc

    Catherine Godrecka-Bareau

    Catherine Godrecka-Bareau, Director of Portfolio Management & Strategy, Biosimilars, Merck Group

    clock

    12:20

    Networking Lunch

    clock

    13:30

    Perspectives on the evolving biosimilars landscape

    Michael Kleinrock

    Michael Kleinrock, Research, Director, IMS Health Inc

  • The Global Biologic Market: understanding the place of biologics in medicine use around the world
  • Learning from the biosimilar experience: European experience can offer some insights into the U.S. future (and some confusion too)
  • Looking ahead to the next five years of biosimilar and biologic evolution
  • clock

    14:10

    Understanding the blurred lines between traditional innovators and generics

    Andrea Laslop

    Andrea Laslop, Head of Scientific Office, Austrian Agency for Health and Food Safety

  • Scientific and quality considerations in demonstrating biosimilarity between the biosimilar and the reference product
  • Reviewing the need to show bioequivalence to the innovator drug based on pharmacokinetic parameters such as rate absorption and bioavailability
  • Understanding the complexity of biosimilar models from a clinical perspective
  • clock

    14:50

    Case Study: The First International Reference Standard

    Michael Tovey

    Michael Tovey, INSERM Director of Research, Laboratory of Biotechnology and Applied Pharmacology, Ecole Normale Supérieure de Cachan

  • Importance of reference Standards for the Development of biosimilars      
  • First WHO International Standard (IS) for the TNF-alpha sRII receptor-Fc fusion protein (Etanercept). 
  • First International Reference (IR) Preparation for anti-drug (anti-Eprex) antibodies
  • Other WHO IS & IRs for biosimilars currently in development
  • clock

    15:30

    Afternoon Tea

    clock

    16:00

    Update: Can biobetters or biosuperiors meet the challenges of best in class molecules and cheaper biosimilars

    Rakesh Dixit

    Rakesh Dixit, Vice President, R&D, Global Head, Biologics Safety Assessment, MedImmune Inc

  • Making biobetters or biosuperiors successful and cost effective through advances in protein engineering and pioneering technologies - case studies of biosuperior vs. biosimilars
  • Evaluating the current innovations in improving existing biologics therapies in diseases with unmet medical needs
  • Identifying which products have significant potential for ‘biosuperior’ development
  • Developing biosuperior protein therapeutics that address sub-optimal, in-market characteristics of currently licensed biologics
  • Examining current active projects in research and development of biosimilar and novel biobetter/biosuperior therapeutic proteins 
  • clock

    16:40

    Impact of Glycosylation on the Biological Functions of Therapeutic Antibodies

    Raju Shantha

    Raju Shantha, Scientific Director, Biologics Research, Janssen Pharmaceuticals, Inc.

    clock

    17:20

    The Great Debate - Interchangeability

    Richard Dicicco

    Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals

  • The determination of interchangeability: satisfying the FDA definition to achieve automatic substitution by the pharmacy without physician consultation
  • Will interchangeability minimize the uncertainty of biosimilar adoption?
  • How does INN naming affect automatic substitution?
  • What will the FDA interchangeability guideline look like?
  • Considerations in the design of switching studies #
  • How will interchangeability affect pricing and reimbursement?
  • Differentiation between the designation or practice of interchangeability in the US and EU
  • Which is more desirable for success: switching existing patients or interchangeability?
  • clock

    18:00

    Chairman’s Closing Remarks and Close of Day One

    Richard Dicicco

    Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Richard Dicicco

    Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals

    clock

    9:10

    The litigation landscape in Europe: where are we now?

    Dominic Adair

    Dominic Adair, Partner, Patent Litigation, Bristows

  • The patent cliff and the patent hurdle – is it real?
  • When litigation begins, are the rules different?
  • Patent challenges in Europe – the EPO and the national courts
  • The future landscape – the Unified Patent Court
  • clock

    9:50

    Challenging the BPCIAs dispute resolution process

    Jim Nelson

    Jim Nelson, Senior Principal and Owner, Adversarial Proceedings/Pharma & Biotech, Schwegman Lundberg Woessner

  • Reviewing the use of IPR at the US PTO PTAB as an alternative to the Patent Dance of the BPCI Act
  • Claim term interpretation, what do these words mean?
  • Touching on the use of amendments
  • clock

    10:10

    Assessing the BPCI and FDA requirements for obtaining the right to sell a Biosimilar in the US

    Robin Chadwick

    Robin Chadwick, Principal, Biotechnology, Schwegman Lundberg Woessner

  • Discussing semi-automated processes to identify and analyze US patents of interest to answer the question whether such patents should be listed on the biosimilar applicant’s proposed list of patents during the BPCI exchange
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Case Study: Creating Biobetters with Improved Efficacy and Safety by Addressing Product Immunogenicity with Tolerogenic Nanoparticles

    Takashi Kei  Kishimoto

    Takashi Kei Kishimoto , Chief Scientific Officer, Selecta Biosciences

  • The forthcoming flood of biosimilars will create a highly competitive, low margin marketplace. There will be a competitive advantage for biobetters that are differentiated based on their efficacy and safety profile
  • Anti-drug antibodies compromise the utility of many biologic drugs by neutralizing drug efficacy, modulating pharmacokinetics, and/or causing adverse events
  • We have developed tolerogenic synthetic vaccine particles (SVP) that are capable of inducing durable immune tolerance to biologic drugs. We will present case examples using tolerogenic SVP with adalimumab and pegylated uricase
  • clock

    11:40

    The fingerprinting approach - Expediting development of Biosimilars

    Magdalena Leszczyniecka

    Magdalena Leszczyniecka, Founder and CEO, STC Biologics Inc

  • Because of the very high cost and length of time associated with biologics development, access to biosimilars at a lower cost with shorter development timelines would make these treatments more accessible to a greater number of patients
  • To realize cost and time savings from biosimilars, the current development model needs to change to follow the generic product development paradigm which requires only one bioequivalence trial
  • STC is currently working on fingerprinting approach to obtain approval on a biosimilar antibody product with only one clinial trial through the use of fingerprinting platform. This concept is described in a detailed publication by FDA’s Steve Kozlowski, indicating that a rigorous “fingerprint” like analytical and nonclinical pharmacological similarity could help lift many of the uncertainties/risks of the biosimilar product compared to the originator, which would decrease the burden of clinical trials conducted only to address any “residual uncertainty” not addressable by in vitro studies
  • clock

    12:20

    Networking Lunch

    clock

    13:30

    What are the opportunities in America - Where will we be in 2018?

    Cliff Mintz

    Cliff Mintz, Senior Writer/Correspondent, Life Science Leader

  • Strengthening long-term strategy to maximise return on investment and to benefit patients
  • How to seek partnership to develop and execute risk mitigation strategies
  • Forecasting market penetration – What are the factoring barriers to entry?
  • clock

    14:10

    Clinical & Regulatory Strategies Encompassing the Needs of East and West

    Gerry McGettigan

    Gerry McGettigan, CEO & Regultory Expert; COO, Kinesys Consulting Ltd (UK); amp biosimilars AG (Germany)

  • What are the key features of a truly global development programme?
  • What obstacles should US / EU biosimilars companies be aware of in Asia and emerging markets
  • What changes do we need in development and regulatory requirements to facilitate truly global developments, and which stakeholders need to make these changes happen?
  • clock

    14:50

    Industry partnerships: Key Success Factors in Biosimilar Space

    Catherine Godrecka-Bareau

    Catherine Godrecka-Bareau, Director of Portfolio Management & Strategy, Biosimilars, Merck Group

  •  Stand-alone situation: high R&D costs, unclear regulatory pathways, uncertain business model, incomplete portfolio
  • We will win together through innovative partnership models
  • Case study of the Airline industry: high fixed costs but low marginal costs
  • Translation to the biosimilar space
  • clock

    15:30

    Afternoon Tea

    clock

    16:00

    Case Study: Where are we now and how will we develop?

  • Biosimilars will soon become number one products – but how to get there?
  • Lessons learned from the first European & US biosimilars
  • Creating a true global biosimilars strategy
  • Similarity exercise, clinical data, extrapolation
  • Monoclonal antibodies, a new milestone for the biosimilars market
  • Why biosimilars have been more successful than biobetters
  • Challenges and opportunities with third wave biosimilars
  • Carsten Brockmeyer

    Carsten Brockmeyer, CEO, Formycon AG

    clock

    16:40

    Assessing emerging markets and enhancing strategies

    Sam Mukherjee

    Sam Mukherjee, Associate Director Biosimilar Commercial Strategy and Portfolio Management, Dr. Reddy's Laboratories Inc.

  • How are emerging markets shifting in BRIC countries
  • Dealing with cost containment
  • How do emerging markets compare to the EU and US regulations
  • clock

    17:20

    Chairman’s Closing Remarks and Close of Day Two

    Richard Dicicco

    Richard Dicicco, Chairman, Harvest Moon Pharmaceuticals


    Head of Scientific Office
    Austrian Agency for Health and Food Safety
    CEO
    Formycon AG
    Director of Portfolio Management & Strategy, Biosimilars
    Merck Group
    Senior Writer/Correspondent
    Life Science Leader
    Partner, Patent Litigation
    Bristows
    CEO & Regultory Expert; COO
    Kinesys Consulting Ltd (UK); amp biosimilars AG (Germany)
    Product Development Expert
    Kinesys Consulting Ltd
    Senior Principal and Owner, Adversarial Proceedings/Pharma & Biotech
    Schwegman Lundberg Woessner
    Biopharmaceutical Regulatory Affairs
    Sandoz Inc
    VP, Regulatory & Clinical Affairs
    Oncobiologics
    Founder and CEO
    STC Biologics Inc
    Research, Director
    IMS Health Inc
    INSERM Director of Research, Laboratory of Biotechnology and Applied Pharmacology
    Ecole Normale Supérieure de Cachan
    Scientific Director, Biologics Research
    Janssen Pharmaceuticals, Inc.
    Vice President, R&D, Global Head, Biologics Safety Assessment
    MedImmune Inc
    Chairman
    Harvest Moon Pharmaceuticals
    Principal, Biotechnology
    Schwegman Lundberg Woessner
    Associate Director Biosimilar Commercial Strategy and Portfolio Management
    Dr. Reddy's Laboratories Inc.
    Medical Director
    Norwegian Medicines Agency
    Chief Scientific Officer
    Selecta Biosciences
    Principal Consultant
    PAREXEL

    Sponsors and Exhibitors

    Platinum Media Partners

    Supporters

    International Clinical and Regulatory Strategies to meet Global Commercial Needs Workshop Preview

    Download

    SMi Speaker Interview Series:Ted Carver, Principal Consultant from PAREXEL

    Download

    SMi Speaker Interview Series: Michael Kleinrock, Director Research Development, IMS Institute for Healthcare Informatics

    Download

    Preliminary List of Attending Organisations in 2015

    Download

    SMi Speaker Interview Series: Gerry McGettigan, CEO & Regulatory Expert from Kinesys Consulting Ltd

    Download

    SMi Speaker Interview Series: Schwegman Lundberg and Woessner P.A

    Download

    Sponsors and Exhibitors


    Schwegman, Lundberg & Woessner

    Sponsors and Exhibitors
    http://www.slwip.com/

    Schwegman Lundberg & Woessner is a nationally recognized boutique IP firm focused on strategic patent procurement with over 140 patent practitioners that have robust backgrounds across a wide spectrum of technology areas. Schwegman's clients include multinational corporations, middle-market businesses, universities, as well as start-ups and individual inventors.

    Media Partners


    Biosimilar News

    Platinum Media Partners
    http://www.biosimilarnews.com

    BiosimilarNews.com is a leading international knowledge and information source about biosimilars. The site helps the industry professionals, clinicians and also the public to find timely and appropriate information about this specific area. Biosimilar News - We keep you up to date.

    Media Partners


    ASD MEDIA

    Supporters
    http://www.asd-network.com

    Professionals in the Aerospace & Defence market use the ASD Media internet platforms to:
    • Be informed on the latest market developments; www.asd-network.com
    • Find the latest business news; www.asd-network.com
    • Find the upcoming events; www.asd-network.com
    • Find companies and organizations; www.asdsource.com
    • Distribute news globally. www.asdwire.com
    The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website.

    For more detailed information please contact with: ASD MEDIA
    Stefan.koopman@asdmedia.nl


    International Pharmaceutical Industry

    Supporters
    http://www.ipimediaworld.com

    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


    Farmavita

    Supporters
    https://farmavitar.com

    FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!


    Bio-Equip

    Supporters
    http://www.bio-equip.cn/

    Established since 1998, Bio-Equip is a leading website for lab equipments, reagents, consumables and bio services. Our users come from different fields like life science, medical research, pharmaceutical, biotechnology, modern agriculture, food safety and environment monitoring. Bio-Equip offer users a complete product directory which involves 158 product ranges among lab equipments, reagents, consumables, lab animals, bio services, cell lines, bio software and books.Serving users through two websites, www.bio-equip.com (Chinese) and www.bio-equip.cn (English), we own over 20,000 registered suppliers and more than 500,000 pieces of product and technical service information with details of product description, price, sample downloading, technical articles and videos.


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Inderscience Publishers

    Supporters
    http://www.inderscience.com

    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


    CanBiotech

    Supporters
    http://www.canbiotech.com

    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


    Select Science

    Supporters
    http://www.selectscience.net/

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover impartial, expert opinion and trusted reviews about latest laboratory equipment and techniques; plus videos, application notes and science news from around the world. Become a member for free today.


    Pharma Marketing News

    Supporters
    http://www.news.pharma-mkting.com/

    Pharma Marketing News is an independent monthly electronic newsletter focused on issues of importance to pharmaceutical marketing executives. It is a service of the Pharma Marketing Network -- The First Forum for Pharmaceutical Marketing Experts -- which brings together pharmaceutical marketing professionals from manufacturers, communications companies, and marketing service providers for wide ranging discussions and education on a multitude of current topics. Pharma Marketing Network & Pharma Marketing News provide executive-level content coupled with permission-based e-marketing opportunities.


    GBI

    Supporters
    http://www.gbihealth.com/

    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


    Frontiers in Biomaterials: The Design, Synthetic Strategies and Biocompatibility of Polymer Scaffolds for Biomedical Application, Volume 1

    Supporters
    http://ebooks.benthamscience.com/book/9781608058761/

    Frontiers in Biomaterials: The Design, Synthetic Strategies and Biocompatibility of Polymer Scaffolds for Biomedical Application, Volume 1 highlights the importance of biomaterials and their interaction with biological system. The need for the development of biomaterials as scaffold for tissue regeneration is driven by the increasing demands for materials that mimic functions of extracellular matrices of body tissues. This eBook covers the latest challenges on the biocompatibility of scaffold overtime after implantation and discusses the requirement of innovative technologies and strategies for the development of materials with long-lasting scaffold and biocompatibility functions.


    http://www.fiercebiotech.com" target="_blank"> sponsor image

    FierceBiotech

    Supporters
    http://www.fiercebiotech.com" target="_blank" class="link" align="right"> http://www.fiercebiotech.com

    FierceBiotech is the biotech industry's daily monitor. Biotech executives rely on FierceBiotech to stay up to speed on biotech corporations, FDA approvals & regulations, industry mergers & acquisitions, clinical trials, and more. Beyond the news of the day, our editors produce in-depth features on industry leaders and up-and-comers, the regulatory environment, and market trends. In addition to our comprehensive website and free email newsletter, you have the opportunity to attend our webinars, peruse our whitepaper library and benefit from our eBooks. Advance your career through our exclusive networking parties and life sciences job board.


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    Labsave

    Supporters
    http://www.labsave.com

    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


    Drug Target Review

    Supporters
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    Drug Discovery World

    Supporters
    http://www.ddw-online.com

    For over a decade DDW has continued to be the ‘must read’ journal within the DD&D Arena. DDW is recognised for voicing the opinions of some of the Industry’s leading luminaries and has become a recognised platform for Industry Gurus to debate some of the more challenging technological and business issues facing the the life science industry. DDW adheres to the maxim..... ‘Turning Science into Business’ DDW examines the advances in new technologies and the associated implications within the context of developing new and efficacious therapeutics. DDW is distinguishable in that it reaches out to a global audience at both bench and boardroom level, allowing both camps to profit from the uncomplicated style of editorial but at the same time challenges our readers to look at new ways to overcome discovery bottlenecks, embrace nascent technologies and build next generation technology platforms.


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


    Ark Patent Intelligence

    Supporters
    http://learnabout.arkpatentintelligence.com/

    If having comprehensive and relevant patent intelligence is important for your work, you might already use GenericsWeb Pipeline Patent Intelligence. Boasting 10 of the top 12 generic companies as clients and world renowned for insightful analysis as the benchmark in quality data, Pipeline Patent Intelligence has been reborn bigger and better under the new brand name Ark Patent Intelligence. Containing everything you already know and love from the previous model, Ark Patent Intelligence has a smarter user interface, key patent analysis and interpretation, increased country coverage and more.


    Lab Bulletin

    Supporters
    http://www.labbulletin.com

    Lab Bulletin is a free online resource for scientists and laboratory professionals where you can catch up on the latest news for laboratory products and services. You will find an extensive directory of laboratory suppliers and manufacturers enabling you to contact companies quickly and easily to request further information. Lab Bulletin also publishes four free monthly E-Newsletters keeping you up-to-date with all of the latest laboratory products and industry news directly to your inbox. We have dedicated E-Newsletters for Chromatography and Spectroscopy, Microscopy and Image Analysis, weekly Industry News updates and our monthly Lab Bulletin E-Newsletter sent out to over 29,000 readers worldwide. To request your free copy click here


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    pharmaphorum

    Supporters
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    Antibodies Online

    Supporters
    http://www.antibodies-online.com

    antibodies-online.com facilitates researchers to find the appropriate antibodies for their respective research project. As an independent and multi-vendor marketplace for research antibodies and thanks to the cooperation with more than 130 different manufacturers, a large selection of Antibodies (over 700,000), ELISA Kits (over 130,000), Secondary Antibodies (17,000), Proteins (130,000), Peptides and Isotype Controls is available. By supporting the Independent Validation Initiative and the Resource Identification Initiative, antibodies-online.com also addresses the important topics of transparent product quality and scientific reproducibility. In addition scientists receive news and detailed information about the individual antibodies from databases such as the PubMed and others.


    Biotechgate

    Supporters
    http://www.biotechgate.com/gate/v3/companies.php

    Biotechgate is a global, comprehensive, life science database covering the Biotech, Pharma and Medtech industries. There are currently over 38,000 company profiles on the Biotechgate database. Biotechgate is commonly used to find product pipelines, collaboration partners, in/out-licensing opportunities and information about technology platforms, management details, new business leads and financing rounds. In addition, our licensing deals database supports companies in negotiating their licensing agreements.


    GenomeWeb

    Supporters
    http://www.genomeweb.com

    GenomeWeb LLC is an independent, privately-held online and print publisher based in New York. Since 1997, GenomeWeb has served the global community of scientists, technology professionals, and executives who use and develop the latest advanced tools in molecular biology research and molecular diagnostics.

    GenomeWeb’s editorial mission is to serve readers with exclusive, in-depth coverage of the technology, institutions, and scientists that make up the worldwide research enterprise of molecular biology. We operate the largest online news organization focused on advanced research tools in genomics, proteomics, and bioinformatics.

    GenomeWeb readers can be found in major biopharmaceutical companies, top research universities, biomedical institutes, and government laboratories.


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    PMR

    Supporters
    http://www.pmrcorporate.com

    PMR (www.pmrcorporate.com) is a British-American company providing market information, advice and services to international businesses interested in Central and Eastern European countries as well as other emerging markets. PMR's key areas of operation include business publications (through PMR Publications), consultancy (through PMR Consulting) and market research (through PMR Research ). Being present on the market since 1995, offering high international standards in projects and publications, as well as providing one of the most frequently visited and top-ranked websites, PMR is one of the largest companies of its type in the region.


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    British Pharmacological Society

    Supporters
    http://www.bps.ac.uk

    The British Pharmacological Society (BPS) is the primary UK learned society concerned with research into drugs and the way they work. Our members work in academia, industry, regulatory agencies and the health services, and many are medically qualified. The Society covers the whole spectrum of pharmacology, including laboratory, clinical, and toxicological aspects. Clinical pharmacology is the medical speciality dedicated to promoting safe and effective use of medicines for patient benefit. Clinical pharmacologists work as consultants in the NHS and many hold prominent positions in UK Universities.


    Pharmaceutical Outsourcing

    Supporters
    http://www.pharmoutsourcing.com

    Pharmaceutical Outsourcing, the journal dedicated to pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry to our 15,000 readers in North America.


    International Journal of Biotechnology

    Supporters
    http://www.inderscience.com/ijbt

    IJBT provides an international forum and refereed authoritative source of information in the field of Biotechnology and Biotechnics, with emphasis on management and economics, as well as the political and social issues. It aims to disseminate knowledge, provide a learned reference in the field, and establish channels of communication between academic and research experts, policy makers and executives in industry, commerce and investment institutions.


    Medical News Today

    Supporters
    http://www.medicalnewstoday.com

    Medical News Today is the largest independent medical and health news site on the web - with over 10,000,000 monthly unique users it is ranked number one for medical news on all major search engines. Medical News Today is used by pharmaceutical, biotech and health organizations, advertising agencies, PR companies and vertical ad networks to deliver targeted campaigns to HCPs, patients and caregivers. To find out how Medical News Today can help you to reach the right audience contact peter@medicalnewstoday.com or visit www.medicalnewstoday.com.


    Sociable Pharma

    Supporters
    http://www.sociablepharma.com

    Sociable Pharma offers a tailored range of research & analysis services to help pharmaceutical companies at all stages of the product lifecycle. We provide customized research & analysis solutions that address the evolving intelligence priorities of each marketed and pipeline product to deliver commercially-focused & highly relevant insight. Our Treatment Pulse business intelligence service helps pharmaceutical companies to understand physicians' perspectives on clinical practice, unmet needs and product differentiation, and continuous primary research analyzes the impact that industry issues will have on the treatment landscape and the implications for each product's competitive positioning.


    International Journal of Environment and Health

    Supporters
    http://www.inderscience.com/ijenvh

    IJEnvH is a fully-refereed scientific journal that provides an international forum for the exchange of information and the advancement of knowledge in the multidisciplinary field of environment and health. The aim of IJEnvH is to stimulate the discussion and communication among scientists, researchers and experts with different background and expertise, involved, at different levels, with the study of environment and health problems.


    American Pharmaceutical Review

    Supporters
    http://www.americanpharmaceuticalreview.com

    Start receiving your free copy today. American Pharmaceutical Review is a review of the drug pipeline from the late discovery phase through manufacturing. American Pharmaceutical Review prides itself on having the most relevant, unbiased and informative editorial in the industry. You will find that all of our editorial is highly technical and written by government agencies, consultants, academics, and large pharmaceuticals companies. American Pharmaceutical Review covers several key topics that are important to drug production:Separations and purification, Drug Delivery, Biopharmaceutical Processing, Biopharmaceutical Development, Formulation development, Manufacturing, Microbiology, Instrumentation, Spectroscopy


    International Journal of Computational Biology and Drug Design

    Supporters
    http://www.inderscience.com/ijcbdd

    IJCBDD, an International Society of Intelligent Biological Medicine official journal, bridges the gap between two very important, complementary disciplines, computational biology and drug design. Through advances in high-throughput genome sequencing and digital imaging technologies, biocomputing, drug design and medical research have unfolded new, predictive sciences such as genomics, proteomics, lipidomics, metabolomics, cytomics and pharmaconomics. These promote new computational, statistical and biomedical approaches to drug design/development, besides unleashing the potential of significantly more accurate, effective personalised diagnosis, therapeutics and patient care.


    International Journal of Behavioural and Healthcare Research

    Supporters
    http://www.inderscience.com/ijbhr

    IJBHR addresses a broad range of original experimental and theoretical papers that deal with behavioural and healthcare concerns. It welcomes high-quality papers from scientists in academic and non-academic organisations as well as business and government worldwide. IJBHR is sponsored by the Business and Economics Society International and the Frontiers in Immunology Research Network.


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    Global Information GII

    Supporters
    http://www.giiconference.com/

    Global Information Inc. (GII), established in 1983, is headquartered in Japan with overseas offices worldwide. GII partners with over 300 market research companies as well as more than 50 global conference organizers to provide comprehensive services to clients from all sectors and perform as an aggregator for research and conference information. GII clients enjoy real time and personalized services through our global presences. For more information, please visit: GII Research Services: http://www.giiresearch.com/about_en.shtml and GII Conferences: http://www.giiconference.com/

    Renaissance Woodbridge Hotel

    515 US Highway 1 South
    Iselin 08830
    USA

    Renaissance Woodbridge Hotel

    Your simple delights will become memorable moments at Renaissance Woodbridge Hotel. This distinctive hotel in Edison, New Jersey, features 269 modern guest rooms, including 42 suites, and more than 25,000 square feet of flexible meeting space. Our hotel's location is centrally located amidst corporate offices and tourist attraction. Our accommodations stand out from other hotels in Edison, NJ, and provide a sophisticated retreat for families and business travelers alike. Marriott's Plug-in panels and 37-inch LCD HD TVs allow guests simultaneous connectivity to laptops, iPods and DVD players. We are one of the most conveniently situated hotels at the crossroads of U.S. Routes 1 and 9. We are also just five minutes from Woodbridge Center Mall, 15 minutes south of Newark Liberty International Airport (EWR) and less than one mile from the Metropark train station. With our premier location and amenities, our Edison accommodations provide an advantageous travel destination.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.